Copyright Reports & Markets. All rights reserved.

Dynamics in Post-pandemic Global Glucagon Like Peptide 2 Receptor Industry: Supply and Demand, Markets and Prices 2021-2027

Request for Sample of this report
Buy now

Table of Contents

    1 Product Introduction and Overview

    • 1.1 Product Definition
    • 1.2 Product Specification
    • 1.3 Global Market Overview
      • 1.3.1 Global Glucagon Like Peptide 2 Receptor Market Status and Forecast (2016-2027)
      • 1.3.2 Global Glucagon Like Peptide 2 Receptor Sales Value CAGR by Region
    • 1.4 Market Drivers, Inhibitors
      • 1.4.1 Market Drivers
      • 1.4.2 Market Inhibitors
      • 1.4.3 COVID-19 Impact Analysis

    2 Global Glucagon Like Peptide 2 Receptor Supply by Company

    • 2.1 Global Glucagon Like Peptide 2 Receptor Sales Volume by Company
    • 2.2 Global Glucagon Like Peptide 2 Receptor Sales Value by Company
    • 2.3 Global Glucagon Like Peptide 2 Receptor Price by Company
    • 2.4 Glucagon Like Peptide 2 Receptor Production Location and Sales Area of Main Manufacturers
    • 2.5 Trend of Concentration Rate

    3 Global and Regional Glucagon Like Peptide 2 Receptor Market Status by Category

    • 3.1 Glucagon Like Peptide 2 Receptor Category Introduction
      • 3.1.1 FE-203799
      • 3.1.2 Glepaglutide
      • 3.1.3 GXG-8
      • 3.1.4 HM-15910
      • 3.1.5 Others
    • 3.2 Global Glucagon Like Peptide 2 Receptor Market by Category
      • 3.2.1 Global Glucagon Like Peptide 2 Receptor Sales Volume by Category (2016-2021)
      • 3.2.2 Global Glucagon Like Peptide 2 Receptor Sales Value by Category (2016-2021)
      • 3.2.3 Global Glucagon Like Peptide 2 Receptor Price by Category (2016-2021)
    • 3.3 North America: by Category
    • 3.4 Europe: by Category
    • 3.5 Asia Pacific: by Category
    • 3.6 Central & South America: by Category
    • 3.7 Middle East & Africa: by Category

    4 Global and Regional Glucagon Like Peptide 2 Receptor Market Status by End User/Segment

    • 4.1 Glucagon Like Peptide 2 Receptor Segment by End User/Segment
      • 4.1.1 Short Bowel Syndrome
      • 4.1.2 Diabetes
      • 4.1.3 Diarrhea
      • 4.1.4 Obesity
      • 4.1.5 Others
    • 4.2 Global Glucagon Like Peptide 2 Receptor Market by End User/Segment
      • 4.2.1 Global Glucagon Like Peptide 2 Receptor Sales Volume by End User/Segment (2016-2021)
      • 4.2.2 Global Glucagon Like Peptide 2 Receptor Sales Value by End User/Segment (2016-2021)
      • 4.2.3 Global Glucagon Like Peptide 2 Receptor Price by End User/Segment (2016-2021)
    • 4.3 North America: by End User/Segment
    • 4.4 Europe: by End User/Segment
    • 4.5 Asia Pacific: by End User/Segment
    • 4.6 Central & South America: by End User/Segment
    • 4.7 Middle East & Africa: by End User/Segment

    5 Global Glucagon Like Peptide 2 Receptor Market Status by Region

    • 5.1 Global Glucagon Like Peptide 2 Receptor Market by Region
      • 5.1.1 Global Glucagon Like Peptide 2 Receptor Sales Volume by Region
      • 5.1.2 Global Glucagon Like Peptide 2 Receptor Sales Value by Region
    • 5.2 North America Glucagon Like Peptide 2 Receptor Market Status
    • 5.3 Europe Glucagon Like Peptide 2 Receptor Market Status
    • 5.4 Asia Pacific Glucagon Like Peptide 2 Receptor Market Status
    • 5.5 Central & South America Glucagon Like Peptide 2 Receptor Market Status
    • 5.6 Middle East & Africa Glucagon Like Peptide 2 Receptor Market Status

    6 North America Glucagon Like Peptide 2 Receptor Market Status

    • 6.1 North America Glucagon Like Peptide 2 Receptor Market by Country
      • 6.1.1 North America Glucagon Like Peptide 2 Receptor Sales Volume by Country (2016-2021)
      • 6.1.2 North America Glucagon Like Peptide 2 Receptor Sales Value by Country (2016-2021)
    • 6.2 United States
    • 6.3 Canada
    • 6.4 Mexico

    7 Europe Glucagon Like Peptide 2 Receptor Market Status

    • 7.1 Europe Glucagon Like Peptide 2 Receptor Market by Country
      • 7.1.1 Europe Glucagon Like Peptide 2 Receptor Sales Volume by Country (2016-2021)
      • 7.1.2 Europe Glucagon Like Peptide 2 Receptor Sales Value by Country (2016-2021)
    • 7.2 Germany
    • 7.3 France
    • 7.4 UK
    • 7.5 Italy
    • 7.6 Russia
    • 7.7 Spain

    8 Asia Pacific Glucagon Like Peptide 2 Receptor Market Status

    • 8.1 Asia Pacific Glucagon Like Peptide 2 Receptor Market by Country
      • 8.1.1 Asia Pacific Glucagon Like Peptide 2 Receptor Sales Volume by Country (2016-2021)
      • 8.1.2 Asia Pacific Glucagon Like Peptide 2 Receptor Sales Value by Country (2016-2021)
    • 8.2 China
    • 8.3 Japan
    • 8.4 Korea
    • 8.5 Southeast Asia
    • 8.6 India
    • 8.7 Australasia

    9 Central & South America Glucagon Like Peptide 2 Receptor Market Status

    • 9.1 Central & South America Glucagon Like Peptide 2 Receptor Market by Country
      • 9.1.1 Central & South America Glucagon Like Peptide 2 Receptor Sales Volume by Country (2016-2021)
      • 9.1.2 Central & South America Glucagon Like Peptide 2 Receptor Sales Value by Country (2016-2021)
    • 9.2 Brazil
    • 9.3 Argentina
    • 9.4 Colombia

    10 Middle East & Africa Glucagon Like Peptide 2 Receptor Market Status

    • 10.1 Middle East & Africa Glucagon Like Peptide 2 Receptor Market by Country
      • 10.1.1 Middle East & Africa Glucagon Like Peptide 2 Receptor Sales Volume by Country (2016-2021)
      • 10.1.2 Middle East & Africa Glucagon Like Peptide 2 Receptor Sales Value by Country (2016-2021)
    • 10.2 Iran
    • 10.3 Israel
    • 10.4 Turkey
    • 10.5 South Africa
    • 10.8 Saudi Arabia

    11 Supply Chain and Manufacturing Cost Analysis

    • 11.1 Supply Chain Analysis
    • 11.2 Production Process Chart Analysis
    • 11.3 Raw Materials and Key Suppliers Analysis
      • 11.3.1 Raw Materials Introduction
      • 11.3.2 Raw Materials Key Suppliers List
    • 11.4 Glucagon Like Peptide 2 Receptor Manufacturing Cost Analysis
    • 11.5 Glucagon Like Peptide 2 Receptor Sales Channel and Distributors Analysis
      • 11.5.1 Glucagon Like Peptide 2 Receptor Sales Channel
      • 11.5.2 Glucagon Like Peptide 2 Receptor Distributors
    • 11.6 Glucagon Like Peptide 2 Receptor Downstream Major Buyers

    12 Global Glucagon Like Peptide 2 Receptor Market Forecast by Category and by End User/Segment

    • 12.1 Global Glucagon Like Peptide 2 Receptor Sales Volume and Sales Value Forecast (2022-2027)
    • 12.2 Global Glucagon Like Peptide 2 Receptor Forecast by Category
      • 12.2.1 Global Glucagon Like Peptide 2 Receptor Sales Volume Forecast by Category
      • 12.2.2 Global Glucagon Like Peptide 2 Receptor Sales Value Forecast by Category
      • 12.2.3 Global Glucagon Like Peptide 2 Receptor Price Forecast by Category
    • 12.3 Global Glucagon Like Peptide 2 Receptor Forecast by End User/Segment
      • 12.3.1 Global Glucagon Like Peptide 2 Receptor Sales Volume Forecast by End User/Segment
      • 12.3.2 Global Glucagon Like Peptide 2 Receptor Sales Value Forecast by End User/Segment
      • 12.3.3 Global Glucagon Like Peptide 2 Receptor Price Forecast by End User/Segment

    13 Global Glucagon Like Peptide 2 Receptor Market Forecast by Region/Country

    • 13.1 Global Glucagon Like Peptide 2 Receptor Market Forecast by Region (2022-2027)
      • 13.1.1 Global Glucagon Like Peptide 2 Receptor Sales Volume Forecast by Region (2022-2027)
      • 13.1.2 Global Glucagon Like Peptide 2 Receptor Sales Value Forecast by Region (2022-2027)
    • 13.2 North America Market Forecast
    • 13.3 Europe Market Forecast
    • 13.4 Asia Pacific Market Forecast
    • 13.5 Central & South America Market Forecast
    • 13.6 Middle East & Africa Market Forecast

    14 Key Participants Company Information

    • 14.1 Zealand Pharma AS
      • 14.1.1 Company Information
      • 14.1.2 Glucagon Like Peptide 2 Receptor Product Introduction
      • 14.1.3 Zealand Pharma AS Glucagon Like Peptide 2 Receptor Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.1.4 SWOT Analysis
    • 14.2 Tasly Pharmaceutical Group Co Ltd
      • 14.2.1 Company Information
      • 14.2.2 Glucagon Like Peptide 2 Receptor Product Introduction
      • 14.2.3 Tasly Pharmaceutical Group Co Ltd Glucagon Like Peptide 2 Receptor Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.2.4 SWOT Analysis
    • 14.3 Takeda
      • 14.3.1 Company Information
      • 14.3.2 Glucagon Like Peptide 2 Receptor Product Introduction
      • 14.3.3 Takeda Glucagon Like Peptide 2 Receptor Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.3.4 SWOT Analysis
    • 14.4 Naia Ltd
      • 14.4.1 Company Information
      • 14.4.2 Glucagon Like Peptide 2 Receptor Product Introduction
      • 14.4.3 Naia Ltd Glucagon Like Peptide 2 Receptor Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.4.4 SWOT Analysis
    • 14.5 Hanmi Pharmaceuticals Co Ltd
      • 14.5.1 Company Information
      • 14.5.2 Glucagon Like Peptide 2 Receptor Product Introduction
      • 14.5.3 Hanmi Pharmaceuticals Co Ltd Glucagon Like Peptide 2 Receptor Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.5.4 SWOT Analysis

    ...

      15 Conclusion

        16 Methodology

        Covid-19 has impacted the supply and demand status for many industries along the supply chain. In this report a comprehensive analysis of current global Glucagon Like Peptide 2 Receptor market in terms of demand and supply environment is provided, as well as price trend currently and in the next few years. Global leading players are profiled with their revenue, market share, profit margin, major product portfolio and SWOT analysis. From industry perspective this report analyses supply chain, including process chart introduction, upstream key raw material and cost analysis, distributor and downstream buyer analysis. This report also includes global and regional market size and forecast, major product development trend and typical downstream segment scenario, under the context of market drivers and inhibitors analysis. According to this survey, the global Glucagon Like Peptide 2 Receptor market is estimated to have reached $ xx million in 2020, and projected to grow at a CAGR of xx% to $ xx million in 2027.

        Segmented by Category
        FE-203799
        Glepaglutide
        GXG-8
        HM-15910
        Others

        Segmented by End User/Segment
        Short Bowel Syndrome
        Diabetes
        Diarrhea
        Obesity
        Others

        Segmented by Country
        North America
        United States
        Canada
        Mexico
        Europe
        Germany
        France
        UK
        Italy
        Russia
        Spain
        Asia Pacific
        China
        Japan
        Korea
        Southeast Asia
        India
        Australasia
        Central & South America
        Brazil
        Argentina
        Colombia
        Middle East & Africa
        Iran
        Israel
        Turkey
        South Africa
        Saudi Arabia

        Key manufacturers included in this survey
        Zealand Pharma AS
        Tasly Pharmaceutical Group Co Ltd
        Takeda
        Naia Ltd
        Hanmi Pharmaceuticals Co Ltd
        Buy now